Improving prescription drug labelling in the US
This article was originally published in SRA
Cathleen O’Connell, Paul Imm and Sandra Kuhn explain how the Food and Drug Administration and other stakeholders are working to improve the quality of content, the timeliness of implementation and the availability of written drug information.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.